RxDoctor Payments Data

Kelly Greer

Psychiatric/Mental Health · Madison, ALNPI 1073180725

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 303 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations.

$5,584in general payments, 2019–2025

Across 303 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$951
  • Otsuka America Pharmaceutical, Inc.$771
  • Corium, LLC$660
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$586
  • Takeda Pharmaceuticals U.S.A., Inc.$517
  • Teva Pharmaceuticals USA, Inc.$484
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$5,48498%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,584 in reported general payments places this provider in the 85th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$31,449
Medicare patients
71
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl33$62,357
RexultiBrexpiprazole23$32,794
Invega SustennaPaliperidone Palmitate16$23,564
TrintellixVortioxetine Hydrobromide25$20,046
Aripiprazole85$3,966
Desvenlafaxine Succinate ErDesvenlafaxine Succinate62$3,372
Bupropion XlBupropion Hcl138$2,931
Vilazodone Hcl29$2,741
Duloxetine Hcl105$2,621
Buspirone Hcl105$2,241
Trazodone Hcl152$1,834
Lurasidone Hcl18$1,803
Atomoxetine Hcl13$1,749
Ziprasidone Hcl24$1,567
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine45$1,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$951$62,35733 claims
Otsuka America Pharmaceutical, Inc.Rexulti$771$32,79423 claims
Johnson & JohnsonInvega Sustenna$381$23,56416 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$517$20,04625 claims
Almatica Pharma LLCSertraline Hcl$253$918104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Madison

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →